The long-term treatment of depression

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 17, 1999, Pages 41-45

  Keller, Martin B ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; PAROXETINE; PLACEBO; SERTRALINE;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DROWSINESS; FEMALE; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOTHERAPY; SIDE EFFECT; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMIPRAMINE; MIANSERIN; PSYCHOTHERAPY; RECURRENCE; SEROTONIN UPTAKE INHIBITORS;

EID: 0032858158     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Angst J. How recurrent and predictable is depressive illness. In: Montgomery SA, Rouillon F, eds. Long-Term Treatment of Depression. Chichester, England: Wiley; 1992:1-13
2. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998;13:63-73
3. Hirschfeld RMA. Long-term drug treatment of unipolar depression. Int Clin Psychopharmacol 1996;11:211-217
4. Kessler RC, McGonagle KA, Shanyang Z, et al. Life-time and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19
5. Keller MB, Hanks DL. Anxiety symptom relief on depression treatment outcomes. J Clin Psychiatry 1995;56(suppl 6):22-29
6. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the medical outcomes study. JAMA 1989;262:914-919
7. Coryell W, Scheftner, Keller MB, et al. The enduring psychosocial consequences of mania and depression. Am J Psychiatry 1993;150:720-727
8. Murray JL, Lopez AD, eds. World Health Organization: The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass: Harvard University Press; 1996
9. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-816
10. Mueller TI, Keller MB, Leon AC, et al. Recovery after 5 years of unremitting major depressive disorder. Arch Gen Psychiatry 1996;53: 794-799
11. Lavori PW, Keller MB, Scheftner W, et al. Recurrence after recovery in unipolar MDD: an observational follow-up study of clinical predictors and somatic treatment as a mediating factor. Int J Meth Psychiatr Res 1994;4:211-229
12. Angst J, Baastrup P, Grof H, et al. The course of monopolar depression and bipolar psychoses. Psychiatr Neurol Neurochir 1973;76:489-500
13. Keller MB. Depression: a long term illness. Br J Psychiatry 1994;165 (suppl 26):9-15
14. Keller MB. Depression: underrecognition and undertreatment by psychiatrists and other health care professionals. Arch Intern Med 1990; 150:946-948
15. Keller MB, Lavori PW, Kleman GL, et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 1986;43:458-466
16. Hirschfeld RMA. Guidelines for the long-term treatment of depression. J Clin Psychiatry 1994;55(12, suppl):61-69
17. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47: 1093-1099
18. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49: 769-773
19. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988;153 (suppl 3):69-76
20. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and lhe prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189-195
21. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992;160:217-222
22. Montgomery SA, Rasmussen JGC, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-188
23. Hirschfeld RMA, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333-340